Skip to main content
logo
Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.2000
+0.1900 (1,900.00%)
At close: Aug 28, 2026

Lyra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.40.41.531.561.360.29
Revenue Growth
-74.06%-74.06%-1.54%14.31%378.25%-
Gross Profit
-0.61-0.610.17-46.47-37.43-29.41
Operating Income
-29.55-29.55-60.73-65.53-54.99-43.62
Net Income
-28.92-28.92-93.44-62.68-55.28-43.51
Earnings Per Share
-18.62-18.62-71.75-62.93-91.41-167.54
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
15.8915.8940.58102.7597.8945.75
Total Debt
30.2630.2634.3826.882.221.45
Net Cash (Debt)
-14.37-14.376.275.8795.6844.29
Net Cash Growth
---91.83%-20.70%116.01%-38.61%
Net Cash Per Share
-9.25-9.254.7676.17158.22170.54

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-28.86-28.86-70.01-63.3-43.39-25.82
Capital Expenditures
-0.12-0.12-2.34-1.05-0.16-3.39
Free Cash Flow
-28.98-28.98-72.35-64.35-43.55-29.21
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-152.76%-152.76%11.34%---
Operating Margin
-7425.38%-7425.38%-3959.13%-4205.90%-4034.48%-15303.51%
Pretax Margin
-7263.32%-7263.32%-6088.40%-4019.32%-4054.66%-15267.72%
Profit Margin
-7266.08%-7266.08%-6090.94%-4023.11%-4055.61%-15267.72%
FCF Margin
-7280.15%-7280.15%-4716.36%-4130.36%-3195.08%-10247.37%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.8913.748.81176.7973.32198.95